AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer



This inaugural conference will feature international leaders in the field who will review the role of the tumor microenvironment, immune involvement, and the microbiome in the pathogenesis of liver cancer. Understanding the mechanism of action of current treatments, biomarkers predicting response, trial design, liquid biopsy and rationale for future combinations will also be explored. Please join in the conversation with basic scientists, physician-scientists, and industry professionals all united towards the common goal of improving research and management of liver cancer.

Plenary Sessions:

  • Molecular Pathogenesis of Hepatocellular Carcinoma: The good and the bad sides of tertiary lymphoid structures in liver cancer; Polyploidy, DNA damage response driver or gatekeeper of chronic liver diseases
  • Inflammation and Liver Cancer: Metabolic control of HCC development; Immune mechanisms driving carcinogenesis in NASH; Mechanisms of immune escape in hepatocellular carcinoma
  • Risk Factors, Surveillance, and Molecular Detection: Epidemiology and emerging risk factors in liver cancer; Surveillance for HCC in at-risk populations: Current perspectives and future directions; Role of liquid biopsy in early detection and assessment of response in HCC; Molecularly-derived prognosis in HCC: Truncal mutations vs acquired aberrations defining outcome
  • Molecular Targeted Therapies in HCC: Molecular mechanisms of response and resistance to TKI in HCC; FDA perspective on accelerated and regular approvals in HCC and cholangiocarcinoma
  • Immunotherapies in HCC: Molecular Mechanisms and Combination Regimens
  • Trial Design and Endpoints in HCC
  • Molecular Pathogenesis and Drivers of Cholangiocarcinoma
  • Molecular Targeted Therapies and Precision Oncology in iCCA
  • Molecular Pathogenesis and Treatment of Hepatoblastoma
Venue: The Westin Copley Place, Boston


May 5-8, 2022


Boston, Massachusetts 02116, United States